Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13775062 | 0.89 | HDAC8 (0.51) | ESR1HDAC8DPP4S1PR1THRA | |
| SCHEMBL15250798 | 0.88 | HDAC8 (0.52) | ESR1HDAC8APPFDPSTTR | |
| SCHEMBL16864064 | 0.87 | HDAC8 (0.49) | ESR1HDAC8APPFDPSTTR | |
| SCHEMBL16864078 | 0.86 | HDAC8 (0.46) | ESR1HDAC8APPFDPSTTR | |
| SCHEMBL28368058 | 0.85 | APP (0.52) | ESR1APPATM | |
| SCHEMBL27463292 | 0.85 | APP (0.52) | ESR1APPATM | |
| SCHEMBL14531370 | 0.85 | HDAC8 (0.45) | ESR1HDAC8APPDPP4S1PR1 | |
| SCHEMBL15959107 | 0.84 | APP (0.45) | ESR1HDAC8APPFDPSTTR | |
| SCHEMBL12652769 | 0.84 | FBP1 (0.47) | ESR1HDAC8APPFDPSTTR | |
| SCHEMBL1549366 | 0.82 | MEN1 (0.56) | ESR1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697304-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (IN) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | ESR1 2155/4885HDAC8 1065/4885APP 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.